Here's Why This Biotechnology Skyrocketed by 439% in December

2026-01-09 06:01:00 ET

Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence . The move followed the company's announcement of positive top-line results from a Phase 3 trial of Deramiocel, a cell therapy for the treatment of Duchenne muscular dystrophy (DMD). However, the story is not quite as simple as a Phase 3 trial hitting its primary endpoints, as you will soon see.

DMD is a genetic disorder occurring in 1 in 3,500 to 5,000 births. There are about 15,000 sufferers in the U.S. and 200,000 worldwide. Nearly entirely impacting boys, it's a severe disorder that causes a weakening of muscles and atrophy because a genetic mutation prevents the body from producing sufficient dystrophin. That matters because dystrophin is a structural protein that helps strengthen muscle fibers and protect them from damage during contraction.

Deramiocel is a cell therapy derived from cardiosphere-derived cells (CDC) that slows disease progression by reducing inflammation and stimulating tissue regeneration in DMD.

Continue reading